Omdia Forecasts Large-Area Display Shipments to Grow 2.9% YoY in 2025 Despite Economic Uncertainty
While growth in 2025 is expected to be smaller than that of 2024, this increase comes in the face of global economic uncertainty and US tariff concerns. Notably, TV and monitor applications are projected to experience negative growth in 2025.
Chinese panel makers, who are expected to take 67.9% of total TV display shipments in 2025 are adopting a conservative approach to increasing LCD TV display shipments to manage panel prices. Similarly, panel makers outside of China are cautious about expanding their monitor display businesses due to poor finance performance.
Figure1. Large-area display shipment latest forecast in 2025 (millions of units)
Large-area LCD unit shipments are expected to increase by 2.4% YoY, reaching 875.5 million in 2025. Pulled-forward demand in 1Q25 has helped to boost the shipment forecast for the year. However, panel makers have little incentive to expand their monitor LCD businesses in 2025 due to financial losses, particularly among non-Chinese manufacturers.
Chinese panel makers are projected to increase monitor LCD shipments by 4.8% YoY while panel makers from other regions will decrease shipments by 12.6% YoY in 2025. Chinese panel makers are also maintaining their production-to-order policy to prevent LCD TV display price erosion starting in 2Q25.
'Interestingly, while LCD TV display unit shipments are expected to decline by 2.1% YoY, shipment area is forecast to grow by 4.9% YoY in 2025 driven by ongoing size migration trends,' said Peter Su, Principal Analyst of Omdia.
Su added, "Large-area OLED unit shipments and shipment area are forecast to grow by 15.5% YoY and 10.4% YoY, respectively, in 2025. However, these figures are lower than the previous forecast (unit shipments up by 20.3% YoY and shipment area up by 12.9% YoY) from our 1Q25 report. This indicates that large-area OLED demand is slowing more than expected due to global economic uncertainty and concerns about potential impacts from the new US tariff policy.'
Regional Market Share
LCD shipments: China is forecast to account for 66.7% of total large-area LCD shipments in 2025, followed by Taiwan with 21.9% and Korea with 8.0%.
Key players: BOE is expected to lead with 36.3% of total large-area LCD shipments, followed by China Star with 16.5% and Innolux with 11.6%.
OLED shipments: Korea is projected to dominate with 85.2% of total large-area OLED shipments, followed by China with 14.8%.
Key players: Samsung Display is expected to lead with 55.1%, followed by LG Display with 30.1% and EDO with 12.0%.
'Tablet PC OLED shipments are forecast to decline by 0.4% YoY in 2025 – an improvement from the previous forecast of -1.9% YoY - but still reflecting negative growth due to slower demand from Chinese PC brands and OEMs," explained Su.
'TV and monitor display shipments are expected to decline in 2025 as panel makers work to protect panel prices and avoid further losses. However, panel makers — particularly those in China — have set aggressive shipment targets for mobile PC displays, where panel makers from other regions still hold a 42.8% market share (as of 2024). This push is aimed at capturing greater market share and is expected to contribute to an overall increase in large-area display shipments during the same period,' concluded Su.
ABOUT OMDIA
Omdia, part of Informa TechTarget, Inc. (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients' strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
Wolverine Worldwide Announces Second Quarter Fiscal 2025 Conference Call for August 6, 2025
ROCKFORD, Mich.--(BUSINESS WIRE)--Wolverine World Wide, Inc. (NYSE: WWW) today announced that it expects to report its second quarter fiscal 2025 financial results on Wednesday, August 6, 2025, at approximately 6:30 a.m. ET. Following the press release, the Company will host a conference call at 8:30 a.m. ET to review results and discuss current business trends. Investors and analysts interested in joining the call are invited to dial 1-800-715-9871 (international callers, please dial 1-646-307-1963) approximately five minutes prior to the start of the call. The conference call will be broadcast live and accessible under 'Webcasts & Presentations' in the Investor Relations section of A recorded replay of the call will be available shortly after the conclusion of the call and remain available until August 13, 2025. To access the telephone replay, dial 1-800-770-2030 (international callers, please dial 1-609-800-9909). The access code for the replay is 9927992. ABOUT WOLVERINE WORLDWIDE Founded in 1883, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world's leading designers, marketers, and licensors of branded casual footwear and apparel, performance outdoor and athletic footwear and apparel, kids' footwear, industrial work boots and apparel, and uniform footwear. The Company's portfolio includes Merrell®, Saucony®, Sweaty Betty®, Hush Puppies®, Wolverine®, Chaco®, Bates®, HYTEST®, and Stride Rite®. Wolverine Worldwide is also the global footwear licensee of the popular brands Cat® and Harley-Davidson®. Based in Rockford, Michigan, for more than 140 years, the Company's products are carried by leading retailers in the U.S. and globally in approximately 170 countries and territories. Wolverine Worldwide is a Great Place to Work® Certified™ company. For additional information, please visit our website,
Business Wire
6 minutes ago
- Business Wire
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release.
Business Wire
6 minutes ago
- Business Wire
Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach
PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Dispatch Bio announced its official launch today, with a mission to engineer a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. Immunotherapies have struggled to effectively treat solid tumors due to two main challenges: the lack of a tumor-specific target and the presence of an immune-suppressive tumor microenvironment. Dispatch's first-in-class Flare platform was specifically engineered to overcome both. It works by delivering a viral vector carrying a novel, universal antigen – called Flare – that precisely tags solid tumor cells while simultaneously breaking down the tumor's inhibitory environment. Once in place, the Flare antigen acts as a beacon, directing the immune system to find and clear the cancer cells — without harming healthy tissue. 'At Dispatch, we are leveraging the ideal tumor target – one that is only expressed by the tumor cells in a patient – and advances in cell therapy engineering and immune system activation at the right place, at the right time, to get to deep and durable responses in cancer,' said Sabah Oney, Ph.D., Chief Executive Officer of Dispatch. 'This work matters deeply to me, as it does to so many whose lives have been touched by cancer. We've built a strong scientific foundation, assembled an exceptional team and developed innovative technology that give us a real shot at making a difference. We are fully committed to doing everything we can for patients who urgently need new options.' Dispatch was established through a pivotal collaboration with the Parker Institute for Cancer Immunotherapy (PICI) and convergence of groundbreaking technologies from the laboratories of Andy Minn, M.D., Ph.D.; Carl June, M.D.; Chris Garcia, Ph.D.; and Kole Roybal, Ph.D. 'With this confluence of innovative technologies from the labs across PICI, we are poised to shift how cancer therapies are conceived,' said Sean Parker, founder and chairman of PICI, as well as a member of Dispatch's board of directors. "We can now pursue the ultimate goal – a universal cure for most solid tumor cancers – using cutting-edge modalities.' Renowned Leadership and Pioneering Scientists Since its founding in 2022, Dispatch has focused on building a world-class leadership team and executing its broad pipeline of programs. The founding team at Dispatch includes: Scientific Co-Founders Andy Minn, M.D., Ph.D., Chair of Immuno-Oncology at Memorial Sloan Kettering Cancer Center Carl June, M.D., PICI Center Director and the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania Chris Garcia, Ph.D., Professor of Structural Biology and Molecular and Cellular Physiology at Stanford School of Medicine, Stanford University Kole Roybal, Ph.D., PICI Center Director and Professor of Microbiology and Immunology at University of California, San Francisco Board of Directors Jeff Marrazzo, Chairman; Co-founder and Former CEO, Spark Therapeutics Jake Bauer, Venture Partner, ARCH Venture Partners John Connolly, Ph.D., Chief Scientific Officer, PICI Robert Nelsen, Co-founder and Managing Director, ARCH Venture Partners Sabah Oney, Ph.D., Chief Executive Officer, Dispatch Sean Parker, Founder and Chairman, PICI Steve Gillis, Ph.D., Managing Director, ARCH Venture Partners Leadership Team Sabah Oney, Ph.D., Chief Executive Officer Barbra Sasu, Ph.D., Chief Scientific Officer Chris Wiwi, Ph.D., Senior Vice President, Technical Operations Jennifer Flaisher, Chief People and Culture Officer Lex Johnson, Ph.D., Co-Founder and Chief Platform Officer Naveen Bazaj, Senior Vice President, Corporate Development Scientific Advisory Board Kole Roybal, Ph.D., University of California, San Francisco; SAB Chairman Andy Minn, M.D., Ph.D., Memorial Sloan Kettering Cancer Center Antoni Ribas, M.D., Ph.D., University of California, Los Angeles Anusha Kalbasi, M.D., Stanford University Brad Rosenberg, M.D., Ph.D., Icahn School of Medicine at Mount Sinai Carl June, M.D., University of Pennsylvania Chris Garcia, Ph.D., Stanford University Christine Brown, Ph.D., City of Hope David Kirn, M.D., 4D Molecular Therapeutics; University of California, Berkeley John Connolly, Ph.D., PICI Kristen Hege, M.D., University of California, San Francisco Lisa Coussens, M.D., Ph.D., FAACR, Oregon Health & Science University Matt Porteus, M.D., Ph.D., Stanford University Series A Funding to Support First-in-Human Studies The Series A syndicate includes founding investors ARCH Venture Partners and PICI, along with Bristol Myers Squibb, the University of Pennsylvania, Stanford University, and Alexandria Venture Investments. With this recently closed funding round, Dispatch has raised a total of $216 million to date. Proceeds from the financing will be used to advance the company's therapeutic candidates into first-in-human clinical studies and beyond, with the first program expected to enter the clinic in 2026. 'We are on the wave of a revolution in cancer therapy, where innovations like Dispatch's tumor-agnostic approach to immunotherapy have the potential to treat a majority of solid tumors,' said Steve Gillis, Ph.D., board member of Dispatch and managing director at ARCH Venture Partners. 'We are excited to support the Dispatch team as they continue to advance their programs.' About Dispatch Bio Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers. To learn more, visit and follow us on LinkedIn and X. About the Parker Institute for Cancer Immunotherapy (PICI) The Parker Institute for Cancer Immunotherapy (PICI) is a 501c3 nonprofit organization driving the next generation of cancer treatment by accelerating the development of breakthrough immune therapies to turn all cancers into curable diseases. Founded in 2016 through the vision of Sean Parker, PICI unites the nation's top cancer centers into a collaborative consortium that fuels high-risk, high-reward science with shared goals, data, and infrastructure. Unlike traditional research models, PICI goes beyond discovery by actively advancing promising innovations through clinical testing, company formation and incubation, and commercialization. PICI has supported more than 1,000 investigators across its network and has a portfolio that includes 17 biotech ventures with over $4B raised in capital. PICI is uniquely positioned to close the gap between scientific discovery and patient access. By integrating scientific excellence with entrepreneurial execution, PICI is reimagining how cures are made, and accelerating their path to the people who need them most. Learn more at About ARCH Venture Partners ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market. For more information, visit
